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Abstract 
 
Background 
Various antidepressants occupy brain serotonin transporter (SERT), decrease platelet serotonin (5-
HT) concentration, and normalize reduced plasma brain-derived neurotrophic factor (BDNF) 
concentrations in depressed patients. Vortioxetine is a recently introduced antidepressant with a 
multimodal mechanism of action. In addition to SERT inhibition, vortioxetine acts via different 5-HT 
receptors. To further elucidate its mechanism of action, we have investigated the effects of 
vortioxetine on platelet 5-HT and plasma BDNF concentrations in patients with major depression. 
Methods 
Platelet 5-HT and plasma BDNF concentrations were determined in 44 healthy subjects at baseline 
and in 44 depressed patients before and after 4 weeks of treatment with vortioxetine (5-15 mg daily). 
Platelet 5-HT concentration was determined using the ortho-phthalaldehyde-enhanced fluorometric 
method, and plasma BDNF concentration using a commercial enzyme-linked immunosorbent assay 
(Quantikine ELISA, R&D Systems). 
Results  
At baseline, platelet 5-HT concentrations did not differ between depressed and control subjects, but 
plasma BDNF values were lower (p=0.011; ω=0.80) in depressed patients than in healthy subjects. 
Vortioxetine treatment significantly (p<0.0001; ω=0.80) decreased platelet 5-HT concentration and 
significantly (p=0.004; ω=0.80) increased plasma BDNF concentration in depressed patients 
compared to their baseline values. Age, gender, and smoking were not significantly associated with 
platelet 5-HT and plasma BDNF concentrations.  
Conclusion 
Despite a novel mechanism of action, vortioxetine shares some common effects with other 
antidepressants. This study is the first to show that, in addition to clinical improvement, 4 weeks of 
treatment with vortioxetine (5-15 mg daily), decreased platelet 5-HT and increased plasma BDNF 
concentrations in depressed patients. 
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Introduction 
Major depressive disorder (MDD) is a highly prevalent and disabling condition, and a leading 
contributor to the global burden of disease (Global burden of disease study 2013 collaborators 2015). 
Antidepressants, mainly selective serotonin (5-hydroxytryptamine (5-HT)) reuptake inhibitors 
(SSRIs) and 5-HT and noradrenaline reuptake inhibitors (SNRIs), are first-line treatment for moderate 
to severe depressive episodes (Malhi et al. 2013). However, because of the limited efficacy, low 
remission rates (Rush et al. 2006), and treatment resistant depression (TRD) (Thomas et al. 2013), 
new treatment strategies are needed (Mihaljevic-Peles et al. 2011). Vortioxetine is a recently 
introduced antidepressant with a novel mechanism of action. While SSRIs and SNRIs are monoamine 
transporter inhibitors (Meyer et al. 2004),
 
vortioxetine is an antidepressant with a multimodal 
mechanism of action. In addition to serotonin transporter (SERT or 5-HTT) inhibition, vortioxetine is 
also a 5-HT3A and 5-HT7 receptor antagonist, 5-HT1B receptor partial agonist, and 5-HT1A receptor 
agonist (Bang-Andersen et al. 2011). 
Like SSRIs and SNRIs, vortioxetine shows a high in vitro affinity for SERT (Bang-Andersen et al. 
2011). However, in contrast to antidepressants such as citalopram, fluoxetine, sertraline, paroxetine, 
or extended-release venlafaxine, which occupy around 80% of striatal SERT (Meyer et al. 2004), the 
occupancy of SERT by vortioxetine in rat ventral hippocampus is only 41% (Mørk et al. 2012). It is 
hypothesized that vortioxetine at therapeutic doses of 5 to 20 mg/day in humans corresponds to 50 to 
80% SERT occupancy (Sanchez et al. 2015), and only high doses of 20-30 mg daily are predicted to 
obtain SERT occupancy comparable to that reached after effective dose of SSRIs. (Stenkrona et al. 
2013). Despite lower SERT occupancy, at least in lower and average daily doses, vortioxetine is an 
effective antidepressant both in short- and long-term studies (Sanchez et al. 2015), exerting its effects 
through a combination of lower SERT occupancy and complex activities on various 5-HT receptors 
(Sanchez et al. 2015).
 
Platelets are an attractive target in neurobiological research due to their 
accessibility and similarities with neurons. Components of the serotonergic system are also located in 
platelets. SERT facilitates 5-HT transport into platelets, is structurally identical to neuronal SERT, 
and is encoded by the same gene as neuronal SERT. Antidepressants, such as paroxetine (Muck-Seler 
et al. 2002),
 
citalopram (Li et al. 2015), sertraline (Pivac et al. 2003), and fluoxetine (Blardi et al. 
2002) that highly occupy brain SERT also markedly decrease platelet 5-HT concentrations. 
Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor involved in neurogenesis and 
neural plasticity of the brain, influencing the stability of the synapses, as well as the release of 
neurotransmitters and neuropeptides (Martinowich and Lu 2008).
 
In addition to brain tissue, BDNF is 
also present in different peripheral tissues, including plasma, blood cells, and mostly platelets. BDNF 
promotes the growth, survival, differentiation, and function of serotonergic neurons (Martinowich and 
Lu 2008), while the regulation of BDNF is mediated by alterations in the serotonergic system (Vaidya 
et al. 1999).
 
There is evidence that both serum and plasma BDNF concentrations are decreased in 
patients with MDD (Piccinni et al. 2008) and antidepressants are reported to normalize these 
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abnormalities (Aydemir et al. 2006; Piccinni et al. 2008; Sen et al. 2008).
 
Some research supports 
((Sen et al. 2008) the use of increased peripheral levels of BDNF as a screening tool for novel 
antidepressant agents, while other research opposes ((Brunoni et al. 2014; Buttenschøn et al. 2015; 
Deuschle et al. 2013; Knorr et al. 2015) this proposition. Antidepressants influence both peripheral 
BDNF and platelet 5-HT concentrations. While decreases in platelet 5-HT concentrations occur 
exclusively during treatment with SSRIs, increases in peripheral BDNF concentration have been 
reported after treatment with antidepressants with different mechanisms of action (Sen et al. 2008), 
such as paroxetine (Yoshimura et al. 2007),
 
sertraline, fluvoxamine (Yoshimura et al. 2014),
 
escitalopram (Aydemir et al. 2006), citalopram (Li et al. 2015),
 
but also
 
mirtazapine (Deuschle et al. 
2013), and milnacipran (Yoshimura et al. 2007).
 
It is assumed that antidepressant-induced inhibition 
of SERT and increased serotonergic transmission via 5-HT4, 5-HT6, 5-HT7 receptor subtypes 
influences BDNF expression by increasing the BDNF mRNA levels and subsequent BDNF signaling 
through tropomyosin receptor kinase B (Galter and Unsicker et al. 2000; Martinowich and Lu 2008). 
Hence, the therapeutic actions of antidepressants may involve adaptive structural and functional 
changes in synaptic plasticity that may be underlined by changes in the expression, secretion, or 
downstream functioning of BDNF (Castrén 2004). 
To the best of our knowledge, there are no data reporting whether vortioxetine affects platelet 5-
HT concentrations or plasma BDNF concentrations in depressed patients. We hypothesized that 
treatment with vortioxetine for 4 weeks is associated with clinical improvement, increases in plasma 
BDNF concentrations, and decreases in platelet 5-HT concentrations in patients with depression, and 
that these effects will be similar to the effects observed after treatment with other SSRIs. 
 
Methods 
Subjects 
The study included both inpatient and outpatient drug-naïve Caucasian Croatians aged 18 years or 
older with a diagnosis of first episode or recurrent episode MDD (referred to as depressed patients). 
Diagnoses were established according to DSM-IV TR criteria, with a minimum score of 18 on the 
Hamilton Depression Rating Scale (HDRS)-17 items. Out of 51 included patients, 44 depressed 
patients completed the study. Drop outs were due to the worsening of symptoms (N=3), drug 
discontinuation (N=2), and refusal to come to the scheduled visits (N=2). Clinical response was 
defined as a ≥ 50% reduction of baseline HDRS scores. Patients were recruited in the University 
Hospital Centre Zagre, and Clinics for Psychiatry Vrapce, Zagreb, Croatia. After an initial interview 
and baseline assessment, patients received 4 weeks of treatment with vortioxetine. At week 4, the 
majority of patients were taking 10 mg vortioxetine daily, while 4 patients were taking 5mg, and 3 
patients were taking 15 mg. There were no serious adverse events during the study: 3 patients reported 
nausea, 1 patient reported abdominal pain, and 1 patient reported headache. 
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The control group comprised 44 healthy drug-naïve Caucasian Croatians, aged 18 years or older, 
unrelated to the study group. The control group donated blood samples during regular check-ups at 
the same time as depressed patients.  
Before sampling, all subjects filled out a detailed questionnaire about their medical history and 
smoking habits. All subjects were matched for gender. Exclusion criteria for all subjects were: acute 
respiratory tract infections; treatment with tryptophan, St John's Worth, antidepressants, mood 
stabilizers, antipsychotics, estrogen replacement therapy, or opioid analgesics at least one month prior 
to inclusion (with the exception of fluoxetine, which had to be withdrawn at least 6 weeks prior to 
study entry); the presence of psychotic symptoms; treatment resistance to the current episode of 
depression; and diagnosis of a comorbid psychotic disorder, bipolar disorder, severe alcohol or other 
substance abuse and dependence, obsessive-compulsive disorder, eating disorder, dementia, and 
severe somatic disorders including poorly controlled arterial hypertension, diabetes and thyroid 
disease. 
Study procedures were approved by the local Ethics Committees and are presented in Table 1. 
Informed consent was obtained from all participants. All procedures were in accordance with the 
ethical standards established by the Helsinki Declaration of 1975 (as revised in 1983).  
 
Blood sample collection 
Whole blood samples were collected in 8.5 ml yellow-top Vacutainer tubes with 1.5 ml of acid citrate 
dextrose anticoagulant. Sampling was performed at 8 a.m., following an overnight fast, and was a part 
of the routine laboratory visits. Platelets were obtained by series of centrifugation of whole blood and 
later from platelet-rich-plasma. Aliquots of plasma were separated for BDNF analysis and stored at -
20 °C. To decrease variability, samples were processed within 1 h of being collected. 
 
Determination of platelet 5-HT concentration 
Platelets were obtained from platelet-rich-plasma and then disrupted by sonication. Platelet 5-HT 
concentrations were determined using ortho-phthalaldehyde (OPT)-enhanced fluorometry. Briefly, 
standards (5-HT) and platelet sonicates (both in duplicates) were incubated with 10 % ZnSO4 and 1N 
NaOH at room temperature for 5 minutes to precipitate proteins. Supernatant was transferred into a 
new glass tube and, after adding 1% L-cysteine and 0.01% OPT, boiled for 10 min. The reaction was 
stopped with 1 N NaOH. The fluorescence of samples was measured on a Varian 
Spectrophotofluorimeter Cary Eclipse, with an exciting wavelength of 345 nm and emitted 
wavelength of 485 nm. Platelet protein levels were measured by the method of Lowry et al. (1951). 
 
Measurement of plasma BDNF concentration 
BDNF concentration in plasma was determined in duplicate using a commercial enzyme-linked 
immunosorbent assay (ELISA) according to the manufacturer’s instructions (Quantikine ELISA, 
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R&D Systems, Minneapolis, USA). Plasma samples were diluted 1:2 according to the manufacturer's 
recommendation. Standards and plasma samples were pipetted into 96-well plates, pre-coated with the 
monoclonal antibody specific for human BDNF. The plate was sealed and incubated for 2 hours at 
room temperature. A monoclonal antibody, specific for human BDNF, conjugated to horseradish-
peroxidase was added to each well. After a 1-hour incubation period at room temperature, the plate 
was washed 3 times with washing buffer to remove any unbound antibody-enzyme reagent. A 
substrate solution was added to the wells and incubated for 30 min at room temperature, protected 
from light. The reaction was terminated by adding 2 N sulfuric acid and the intensity of the color was 
measured using a microplate reader set to 450 nm with wavelength correction set to 570 nm. The 
intra- and inter-assay coefficients of variations were less than 10%. The concentrations of samples in 
each plate were calculated based on a standard curve. 
 
Statistical evaluation 
The results were expressed as means ± standard deviation, and evaluated with Sigma Stat 3.5 (Jandel 
Scientific Corp., San Jose, California, USA). Normality of data distribution was confirmed with the 
Kolmogorov-Smirnov test. Student t-test was used to compare data between healthy subjects and 
depressed patients. Paired t-test was used to compare data within depressed patients subdivided into 
those before and after treatment. A multiple linear regression analysis was used to check for the 
influence of age, gender, and smoking on plasma BDNF and platelet 5-HT concentration, both at 
baseline and after treatment. All tests were two-tailed and corrected α was set at 0.025. G*Power 3 
Software was used to determine a priori sample size and actual power. For the t-test (with α=0.025; 
power (1 – β)=0.800; a large effect size (ω=0.80)), total desired sample size was 52, and the actual 
sample size was 84. For the paired t-test (with α=0.025; power (1 − β)=0.800; a medium effect size 
(ω=0.30)), total desired sample size was 34, and the actual sample size was 44. For multiple 
regression analysis (with α=0.05; power (1 − β)=0.800; a medium effect size (ω=0.15); number of 
predictors=3), total desired sample size was 43, and the actual sample size was 44. Therefore, we had 
the appropriate sample size and statistical power to detect significant differences in the studied 
groups. 
 
Results 
Sample characteristics 
Demographic and clinical features of patients are presented in Table 2. Healthy control subjects were 
49.8±8.3 years old and did not differ in age (t=1.27; df=86; p=0.208; Student’s t-test) from depressed 
patients (Table 2). Regarding smoking, there were no significant differences (2=0.056, df=1; 
p=0.813) in the frequency of smokers and nonsmokers between depressed patients and healthy control 
subjects. As expected, the total HDRS scores of patients significantly (p=0.0001) decreased after 4 
weeks of vortioxetine treatment compared to baseline scores (Table 2). 
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Platelet 5-HT and plasma BDNF concentration 
Multiple linear regression analyses evaluated the possible influence of age, gender, and smoking 
status on platelet 5-HT, both at baseline and after treatment. Using platelet 5-HT concentrations as the 
dependent variable, and age, gender, and smoking as independent variables, the model was not 
significant before (F(3, 40)=0.233; p=0.873; Radj
2
=-0.061) or after (F(3, 40)=1.867; p=0.152; 
Radj
2
=0.061) treatment with vortioxetine. Age (p=0.960), gender (p=0.957), and smoking (p=0.414) 
did not significantly affect platelet 5-HT concentrations before treatment. After vortioxetine 
treatment, gender (p=0.573) and smoking (p=0.245) were not significantly associated with platelet 5-
HT concentrations. Since age was marginally associated with platelet 5-HT concentrations (p=0.039), 
after treatment, Spearman's coefficient of rank correlation was used assess this relationship. It 
revealed no significant correlation between platelet 5-HT concentrations and age in patients before 
(r=0.159; p=0.304) or after (r=-0.065; p=0.673) treatment. 
Multiple linear regression analysis used plasma BDNF concentration as the dependent variable, 
and age, gender, and smoking as independent variables. It revealed that the model was not significant 
either at baseline (F(3, 40)=1.490; p=0.233; Radj
2
=0.035), or after treatment (F(3, 40)=2.231; p=0.101; 
Radj
2
=0.084). This lack of significant association was due to a lack of significant effect of age 
(p=0.723), gender (p=0.136), and smoking (p=0.088) on plasma BDNF concentration before 
treatment, or a lack of significant effect of age (p=0.213) and gender (p=0.259) on plasma BDNF 
concentration after vortioxetine treatment. Although the model was not significant, as the significant 
effect of smoking (p=0.023) was detected after treatment, to further evaluate the possible impact of 
gender and smoking on plasma BDNF concentration all subjects were subdivided according to gender 
or smoking (Table 3). 
Platelet 5-HT and plasma BDNF concentrations did not differ significantly among healthy subjects 
or among depressed patients before or after treatment, all of whom were subdivided according to 
smoking status and gender (Table 3). Consequently, in the further analyses subjects were merged 
according to the gender and according to the smoking status. 
Individual data for platelet 5-HT and plasma BDNF concentrations are presented in Figs. 1 and 2. 
Relative changes in platelet 5-HT and BDNF concentrations after vortioxetine treatment are shown in 
Table 4. 
Platelet 5-HT concentrations were similar (t=0.308; df=86; p=0.759; Student’s t-test) between 
control subjects and depressed patients before treatment (Fig. 1). BDNF concentrations differed 
significantly (t=2.594; df=86; p=0.011; Student’s t-test) between control subjects and depressed 
patients before treatment, as control subjects had significantly higher plasma BDNF concentrations 
than depressed patients at baseline (Fig. 2). 
Vortioxetine treatment for 4 weeks significantly affected platelet 5-HT concentrations in depressed 
patients. Platelet 5-HT concentrations were significantly decreased (t=7.068; df=43; p<0.0001, Paired 
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samples t-test) after 4 weeks of vortioxetine treatment compared to baseline values (Fig. 1). In 
addition, depressed patients had significantly (t=6.920; df=86; p<0.0001, Student t-test) lower platelet 
5-HT concentrations than control subjects after vortioxetine treatment. (Fig. 1).  
In depressed patients, plasma BDNF concentration was significantly increased (t=2.997; df=43; 
p=0.0045, Paired samples t-test) after vortioxetine treatment compared to their baseline plasma BDNF 
concentration (Fig. 2). This treatment “normalized” plasma BDNF concentration in depressed patients 
since BDNF concentrations did not differ significantly (t=0.570; df=86; p=0.570) from the BDNF 
values in control subjects (Fig. 2). 
To evaluate (Paired samples t-test) the possible relationship between platelet 5-HT and plasma 
BDNF concentrations and the first or the recurrent episode of depression, patients were subdivided 
into first episode and recurrent episode depression. Platelet 5-HT concentrations were similar in 
patients both with first episode or recurrent episode depression, before (t=0.516; df=42; p=0.609) and 
after (t=1.324; df=42; p=0.193) vortioxetine treatment. Similarly, plasma BDNF concentration did not 
differ significantly (t=1.464; df=42; p=0.151) between patients in the first or the recurrent episode of 
depression, before (t=-1.464; df=42; p=0.151) or after (t=-0.287; df=42; p=0.775) vortioxetine 
treatment. 
To assess the possible correlation between changes in the HDRS scores and plasma BDNF or 
platelet 5-HT concentrations, and between plasma BDNF and platelet 5-HT, Pearson’s coefficient of 
rank correlation was used. It revealed no significant correlation between changes in the HDRS scores 
and plasma BDNF (r=0.063; p=0.698) or platelet 5-HT (r=0.231; p=0.151) respectively, or between 
changes in plasma BDNF and platelet 5-HT concentrations (r=0.198; p=0.204). 
  
Discussion 
To the best of our knowledge, this is the first study that compared platelet 5-HT and plasma BDNF 
concentrations in depressed patients before and after 4 weeks of treatment with the novel 
antidepressant vortioxetine (5-15 mg daily). The main findings from the present study are: 1) 
vortioxetine treatment significantly decreased platelet 5-HT concentration and HDRS scores when 
compared to values before treatment; 2) this treatment significantly increased plasma BDNF 
concentration.  
According to our results, vortioxetine (5-15 mg/day) decreased platelet 5-HT concentration, 
similar to the effect of other SSRIs (Blardi et al. 2002; Li et al. 2015; Muck-Seler et al. 2002; Pivac et 
al. 2003).
 
This finding is in line with vortioxetine’s high SERT affinity in vitro (Bang-Andersen et al. 
2011), but in slight discordance with only partial SERT occupancy detected in rats
 
(Bang-Andersen et 
al. 2011) and humans (Areberg et al. 2012). The majority of our patients received 10 mg of 
vortioxetine daily, and this dose is reported to correspond to 63% of SERT occupancy (Areberg et al. 
2012),
 
which was below the SSRI/SNRI efficacy threshold of 80%. Our study is the first to show in 
vivo effects of vortioxetine on platelet 5-HT concentrations in depressed patients, as other studies 
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have only been conducted on healthy and younger subjects (Areberg et al. 2012; Stenkrona et al. 
2013).
 
A meta-analysis of molecular imaging data revealed reductions of around 10% availability in 
5-HT reuptake sites  in different brain regions in drug-naïve depressed patients compared to healthy 
subjects (Uebelhack et al. 2006),
 
which were further reduced with increased age (Gryglewski et al. 
2014; Rominger et al. 2015).
 
SSRIs have been found to modulate 5-HT concentration in a similar 
manner in platelets and neurons (Yubero-Lahoz et al. 2013),
 
and theoretically, the higher the central 
SERT occupancy, the lower the platelet 5-HT concentration. We speculate that in our patients, 
vortioxetine has sufficiently inhibited SERT in platelets to cause marked decreases in platelet 5-HT 
concentrations. In line with previous reports (Muck-Seler et al. 2002; Uebelhack et al. 2006),
 
no 
differences in platelet 5-HT concentrations between depressed patients and healthy controls were 
found. In our study, and in agreement with previous data (Nenadic Sviglin et al. 2011),
 
platelet 5-HT 
concentrations were not affected by age and gender, both in healthy controls and depressed patients. 
This result corresponds with the absence of an association between smoking and platelet 5-HT 
concentrations in healthy subjects (Klein et al. 2007; Launay et al. 2009) or psychiatric patients 
(Kovacic et al. 2008). 
The present study also detected increased plasma BDNF concentration in depressed patients after 4 
weeks of treatment with vortioxetine. Our results are in agreement with reports showing increased 
plasma BDNF in depressed patients treated with SSRIs such as sertraline (Brunoni et al. 2014),
 
citalopram (Haghighi et al. 2013),
 
fluoxetine or desvenlafaxine (Ghosh et al. 2015),
 
and paroxetine 
(Yasui-Furukori et al. 2011), and in responders to paroxetine, citalopram and venlafaxine (Lee and 
Kim 2008). In our study depressed patients had decreased plasma BDNF concentrations compared to 
healthy subjects, consistent with findings across studies (Fornaro et al. 2015; Lee and Kim 2008; 
Piccinni et al. 2008; Yoshimura et al. 2007),
 
although these remain limited and insufficient for meta-
analysis (Polyakova et al. 2015). 
While we investigated the influence of vortioxetine on BDNF concentration in plasma, many 
studies have determined the effect of antidepressants on serum BDNF concentration. The majority of 
serum BDNF originates from platelets and therefore, plasma reflects short-term, while serum reflects 
long-term BDNF content (Polyakova et al. 2015). However, it is still unclear whether plasma and 
serum BDNF concentrations are interdependent (Polyakova et al. 2015). It has been reported that both 
plasma and serum BDNF concentrations are decreased in depressed patients, and that plasma BDNF 
concentration increases, while serum BDNF levels remains low at the 1st, 3rd, 6th and 12th month of 
antidepressant treatment (Piccinni et al. 2008). Though it is assumed that serum BDNF is stored in 
human platelets (Fujimura et al. 2002), the source of plasma BDNF is still not fully explained. Plasma 
BDNF could originate from vascular endothelial and smooth muscle cells (Nakahashi et al. 2000), or 
it may be released by macrophages and lymphocytes after their activation (Kerschensteiner et al. 
1999). There are also indications that BDNF can cross the blood-brain barrier, which is why neurons 
and glia could also be the source of circulating BDNF (Karege et al. 2002; Pan et al. 1998). 
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Several limitations in our study should be addressed. Exercise levels that may increase BDNF 
concentration
 
(Rasmussen et al. 2009) were not determined. Female subjects were not assessed for 
menopausal status or phase of menstrual cycle. However, no associations were found between plasma 
BDNF levels and luteinizing hormone, follicle-stimulating hormone, estrogen and progesterone levels 
(Baek et al. 2014). Furthermore, in our study age and gender were not significantly associated with 
plasma BDNF.
 
The main advantage of our study is that it is the first in which platelet 5-HT and 
plasma BDNF concentration were determined simultaneously in depressed patients before and after 
treatment with a novel antidepressant vortioxetine. Also, our study included only drug-naïve Croatian 
Caucasians, and the findings revealed significant effects of vortioxetine treatment on platelet 5-HT 
and plasma BDNF concentrations. The study had an appropriate sample size and the statistical power 
to detect significant differences between groups. 
In conclusion, 4 weeks of treatment with vortioxetine decreased platelet 5-HT and increased 
plasma BDNF concentrations in patients with MDD. These results suggest that in spite of a novel and 
distinct mechanism of action, vortioxetine shares some common effects with other antidepressants. 
 
Compliance with ethical standards 
Study procedures were approved by the local Ethics Committees. Informed consent was obtained 
from all participants. All procedures were in accordance with the ethical standards laid out in Helsinki 
Declaration of 1975 (as revised in 1983). The authors declare that they have no conflicts of interest in 
relation to the current study and in general. 
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Table 1 Study procedures for patients with major depressive disorder 
Procedure Baseline Week 4 
Initial interview, Inclusion/exclusion criteria, Signing 
ICD, Demographic data 
x  
HDRS-17 x x 
Platelet serotonin concentration x x 
Plasma BDNF concentration x x 
BDNF, brain-derived neurotrophic factor; HDRS, Hamilton Rating Scale for Depression 
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Table 2 Demographic and clinical data of patients with major depressive disorder 
 N=44 
Sex (male/female) 14/30 
Smoking (yes/no) 12/32 
Depressive episode (first or single/recurrent) 22/22 
Family history of depression (yes/no) 15/29 
Suicide attempt (yes/no) 3/41 
Age 52.9 (13.7) 
HDRS score:  
 at baseline 30.3 (5.6) 
 after treatment 11.9 (7.1)
a
 
Values for age and HDRS score are presented as mean (standard deviation) 
a
 vs HDRS baseline score (t=-21.33; df=40; p<0.0001) 
BDNF, brain-derived neurotrophic factor; HDRS, Hamilton Rating Scale for Depression 
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Table 3 Platelet serotonin concentrations and concentration of plasma brain-derived neurotrophic factor (BDNF) in healthy subjects and patients with major 
depressive disorder (evaluated before or after vortioxetine treatment) subdivided according to smoking status and gender 
 Platelet serotonin  Plasma BDNF 
  Depressed subjects   Depressed subjects 
 Healthy subjects At baseline After treatment  Healthy subjects At baseline After treatment 
Smoking        
Yes 1.59 (0.74) 1.29 (0.48) 0.62 (0.34)  0.56 (0.29) 0.51 (0.43) 0.87 (0.82) 
No 1.37 (0.61) 1.47 (0.63) 0.71 (0.33)  0.58 (0.32) 0.36 (0.25) 0.53 (0.32) 
Student’s t-test  
(df=42) 
t=-1.02; p=0.316 t=0.86; p=0.398 t=0.85; p=0.404  t=0.20; p=0.842 t =-1.42; p=0.163 t=-1.94; p=0.059 
        
Sex        
Male 1.37 (0.60) 1.40 (0.61) 0.71 (0.39)  0.62 (0.32) 0.33 (0.24) 0.55 (0.25) 
Female 1.47 (0.68) 1.40 (0.60) 0.67 (0.29)  0.55 (0.31) 0.44 (0.32) 0.66 (0.60) 
Student’s t-test  
(df=42) 
t=0.50; p=0.622 t=0.01; p=0.993 t=-0.34; p=0.737  t=-0.71; p=0.483 t=1.15; p=0.256 t=0.34; p=0.527 
Values are presented as mean (standard deviation) 
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Table 4 Changes in platelet serotonin and plasma brain-derived neurotrophic factor (BDNF) 
concentrations in patients with major depressive disorder after vortioxetine treatment, compared to 
measurements before treatment. Data are shown as the percentage change (%) from baseline. 
Sample ID Δ platelet serotonin Δ plasma BDNF 
1 83.9 499.4 
2 7.6 -78.7 
3 57.1 1245.8 
4 59.6 455.7 
5 72.1 1867.3 
6 73.3 172.9 
7 51.5 729.2 
8 42.5 -73,1 
9 43.8 20,6 
10 54.4 32,8 
11 59.2 133.4 
12 57.4 30.5 
13 52.6 31.8 
14 77.5 -5.0 
15 23.4 69.6 
16 45.2 208.2 
17 -46.5 13.0 
18 73.8 -37.6 
19 29.7 900.2 
20 -70.5 135.2 
21 38.4 -25.3 
22 5.8 192.2 
23 48.3 16.3 
24 59.2 801.7 
25 36.9 54.1 
26 71.7 -28.1 
27 -49.4 47.1 
28 63.4 -76.3 
29 9.4 186.1 
30 59.3 44,4 
31 77.9 -32.6 
32 -108.7 -20.8 
33 83.1 -47.1 
34 65.8 -23.7 
35 73.6 194.0 
36 42.2 68.4 
37 75.1 272.0 
38 8.9 11.7 
39 47.1 -25.6 
40 37.4 190.4 
41 12.2 213.8 
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42 82.6 164.9 
43 21.3 26.3 
44 72.7 -3.6 
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Fig. 1 Dot-plot of platelet serotonin (5-HT) concentration in healthy subjects and depressed patients 
at baseline and after 4 weeks of treatment with vortioxetine. Bold line and whiskers represent mean  ± 
1 standard deviation. 
*p<0.0001 vs. patients at baseline (Paired samples t-test); #p<0.0001 vs. control subjects (Student t-
test) 
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Fig. 2 Dot-plot of plasma brain-derived neurotrophic factor (BDNF) concentration in healthy 
subjects and depressed patients at baseline and after 4 weeks of treatment with vortioxetine. Bold line 
and whiskers represent mean  ± 1 standard deviation. 
*p=0.0045 vs. patients at baseline (Paired samples t-test); #p<0.0001 vs. control subjects (Student t-
test) 
 
